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In 1974 we reported the transient  appearance of an unexpected mouse allotype (1). 
An antigen  indistinguishable  from the BALB/c IgG2~ allotype (Ig-la) l was detected 
in a congenic partner strain of BALB/c (C.B-17). However, C.B-17 mice were bred to 
exclude Ig-la and were typed homozygous for the  gene that  controls production of 
the IgG2a allotype of C57BL/Ka mice (Ig-lb). Because Ig-la was normally undetect- 
able in C.B-17 mice, we referred to it as a  hidden allotype (Ig-la'). 
Other  investigators  have also  noted  nonallelic  behavior of Ig allotypes.  Lobb  (2) 
and Rivat et al.  (3)  reported that  human blood lymphocytes stimulated  with phyto- 
hemagglutinin, or in mixed lymphocyte cultures, produce Gm allotypes not found in 
the  serum  of the  donor,  although  it  should  be  added  that  other  laboratories  (4,  5) 
have not been able to confirm this work.  Pothier  (6)  observed that  Syrian hamsters 
injected  with  human  lymphoid tumors produce human  allotype markers;  one such 
recipient animal was briefly positive for Gm (a) and Gm (z), even though the injected 
cells  came  from  a  Gm  (a-)  donor.  For  rabbits,  too,  there  are  examples  in  which 
allotypes not anticipated  from genetic  data  have been detected.  Strosberg et  al.  (7) 
first  noted the appearance of three group a  allotypes and three group b  allotypes in 
a  rabbit  immunized against Micrococcus lysodeickticus.  Mudgett et al.  (8)  followed with 
the observation that normal rabbits of the as allotype sometimes show small quantities 
of al and a3 in their serum  (--<1% of the as concentration).  Further,  the examination 
of over 119 rabbits showed that very low concentrations of al, as, or a3 allotypes could 
be  found  in  rabbits  of all  nominal  alloytpe  combinations.  Such  hidden  or  latent 
allotypes  appeared  transiently  in  microgram  quantities  (per  milliliter  of serum)  in 
-~50%  of the  rabbits  examined  (8).  Latent  rabbit  allotypes  for  both  variable  and 
constant regions have now been observed in several laboratories  (9,  10,  1 1). 
All of the preceding serological observations are difficult to interpret because anti- 
allotype sera are likely to contain subspecificities of antibody directed against different 
allotypic determinants.  This is illustrated  for rabbit  allotypes by the findings of van 
der Loo et al.  (12) and Mage et al.  (13); namely, that anti-as made in a3a3, but not in 
alaa or ata3 rabbits, can see as-like determinants in hyperimmunized ala3 rabbits. This 
means  that  it  is  critical  to distinguish  whether  a  hidden  allotype  is  in  fact  a  leaky 
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nominal  allotype derived  from  a  repressed  gene  or  cell, or  a  subspecificity  (cross- 
reaction)  undetectable  by  conventional  typing  methods.  Mindful  of this  problem, 
Mudgett-Hunter  et  al.  (11)  have  recently applied more stringent  assays to measure 
latent a  allotypes; they conclude that detection of such antigens cannot be attributed 
to weak cross-reactions or to technical artifact. 
Relevant  to  the above, we have  used  a  radioimmune  assay to analyze the  Ig-la' 
found in two pooled serum samples from different Igb-congenic BALB/c strains, one 
from  C.B-17,  and  the other  from  BAB/14  mice.  We  report  direct  measurements  of 
competitive and noncompetitive binding of Ig-la' to specifically purified anti-Ig-la. 
Our results indicate that  Ig-la' and Ig-la are serologically identical. 
Materials  and  Methods 
Mouse-Strain AUotypes.  Ig allotypes of BALB/c (Iga) and C57BL (Ig  b) are noted according to 
the  nomenclature of Herzenberg et  al.  (14).  Of particular interest  is  the IgG2a  allotype of 
BALB/c  (Ig-la)  because  an  antigen  indistinguishable from  Ig-la  (Ig-la')  was  detected  in 
certain  7S  Ig preparations of BAB/14  and  C.B-17  pooled mouse sera. As allotype-congenic 
partners  of BALB/c  mice,  the  latter two  strains  were  made  homozy~ous  after  14  and  17 
backcross generations for C57BL/Ka genes that control production of Ig  allotypes (i.e., Ig-lb, 
Ig-2b, etc.) 
7S  Ig  Preparations.  Ig-la containing  7S  Ig  of BALB/c  and  of C.B-17  in  which  Ig-la- 
producing plasmocytomas (MOPC  173, LPC-1  or UPC-10)  were growing, was obtained by 
precipitating serum Ig with 50% (NH4)2SO4 and passing it over DEAE-cellulose columns (2.5 
×  30 cm). The columns were equilibrated with 0.02M  PO4 buffer, pH 7.4.  7S Ig of C.B-17, 
BAB/14, C57BL/6  (B6), and of C57BL/Ka was obtained in the same manner. BAB/14 (pool 
D)  and  C57BL/Ka  pool  sera were  gifts  from  Dr.  M.  Weigert of the  Institute  for  Cancer 
Research, the Fox Chase Cancer Center, Philadelphia, Pa. and Dr. M. Potter of the National 
Cancer Institute, Bethesda, Md., respectively. Fc and Fab fragments of papain-digested M173 
were isolated according to Fahey and Askonas (15). 
Radiolabeling of 7S Ig.  The labeling of 7S Ig (220 gg) with 131I or 125I was according to the 
chloramine T  method of Hunter (16). This was done in sealed V-shaped vials containing 2 mCi 
of isotope (New England Nuclear, Boston, Mass.). To remove unreacted isotope and small ra- 
diodamaged protein products, each preparation was passed over a column of Sephadex G-50 
(1  X  35 cm, Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) topped by 
a mixed bed (2 cm) of ion-exchange resin (Amberlite IR 4B, Mallinckrodt Inc., St. Louis, Mo.; 
and Bio-Rad AG,  1 X  8 cm, Bio-Rad Laboratories, Richmond, Calif.). The resulting prepa- 
rations showed specific activities ranging from 8 to 12  ×  106 cpm/#g protein. 
Radioimmune Assay 
CONSTRUCTION OF IC-IA-REACTlVE  WELLS.  Microtiter wells (Cooke Engineering Co.,  Alex- 
andria, Va.)  were  made specifically Ig-la-reactive by a  procedure described elsewhere (17). 
This entailed successive additions, incubations, and washings as indicated: (a) 50 gI of 0.01% 
bovine serum albumin (BSA) containing 1 gg of Ig-la or Ig-la Fc (from M173) for 1 h; (b) 200 
btl of 0.5% BSA for 0.5 h;  (c) 50 gl of a  1:200 dilution of B6 anti-Ig-la serum (1) for -->3 h;  (d) 
200 gl of 2.5  X  10  -~ M  glutaraldehyde for 0.5 h; and (e) 200 gl of 0.5% BSA for 0.5 h. Control 
wells for nonspecific binding were coated in step a with BSA only or BSA containing 2/~g of B6 
7S Ig; subsequently, the wells were treated as indicated in steps b-e. 
NONCOMPETITIVE BINDING OF 112511IG-IA AND [13111IG-IA' TO IG-IA-REACTIVE WELLS.  The binding 
of [t2sI]Ig-la or [13q]Ig-la' at  4°C  was  measured  under conditions of antibody and  antigen 
excess.  Increasing quantities of labeled antigen were added to Ig-la-reactive wells;  16 h later, 
the wells were washed, cut out, and analyzed for radioactive counts (gamma counter, IN/US 
Service Corp.,  Fairfield, N. J.).  All counts  per minute values were corrected for nonspecific 
binding which usually amounted to <1% of the total counts per minute added. 
COMPETITIVE  BINDING  OF  [1251]IG*IA AND  [131I]IG-IA'  TO  IG-IA-REACTIVE  WELLS.  Competitive 
binding between a fixed quantity of [125I]Ig-la (2.5 gg/well) and varying quantities of Ig-1 a or C.  L.  DEWITT  AND  M.  J.  BOSMA  353 
Ig-la' was done at 4°C  in a  reaction vol of 50 btl;  16 h  later, the wells were washed, cut out, and 
counted. 
By  using  different  labeled  forms  of  both  competitors  ([12sI]Ig-la  and  [131I]Ig-la'),  direct 
measurements  of their binding could be made.  For this, increasing concentrations of each were 
mixed  together and added  in 50-~1 vol to Ig-la-reactive  wells. 
Results 
Detection of Ig-la'  in  7S Ig from Pooled Serum of C.B-17  and  BAB/14  Mice.  Five 
different preparations of 7S Ig, three from pooled sera of C.B-17  (A, B, C), and two 
from pooled sera of BAB/14  mice  (D,  E),  were tested  for Ig-la'. The C.B-17  pools 
were obtained from different groups of mice (45 or more, 3-6 mo of age) at different 
times in the year 1976.  The two BAB/14 pools were also collected at different times: 
pool  D  came  from  a  BAB/14  colony  maintained  at  The  Salk  Institute  (La Jolla, 
Calif.)  and  pool  E  from  members of the  same  BAB/14  colony  maintained  at  the 
Institute for Cancer Research, The Fox Chase Cancer Center,  Philadelphia,  Pa. Fig. 
1 shows that the A and D preparations could completely inhibit the uptake of [x2sI]Ig- 
la to Ig-la-reactive tubes. The slopes of competitive curves A  and D  were the same 
as those obtained with Ig-1 a myeloma protein (M 173) and 7S Ig of BALB/c. However, 
A  and  D  were shifted  to the right  of M173  by ~3  orders of magnitude,  suggesting 
these preparations contained only ~0.1% of the Ig- 1  a found in M 173. Another C.B- 17 
preparation  (B)  not shown, was five times less effective as a competitor than the one 
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FIG.  l.  Antigen competition  in Ig-la-reactive wells between 50 ~g/ml of [~2'~I]]g-la (from M173) 
and varying concentrat ions of unlabeled Ig- I a of M 173 (A); Ig- I a Fab of M 173 (A); 7S Ig of BALB/ 
c (C)); 7S Ig of C.B-17, preparation A  (X);  7S Ig of BAB/14, preparation  D  (O);  7S Ig of C57BL/ 
Ka  (l"l); and  7S Ig of C57BL/6  (').  The  percentage of [1251]Ig-la  bound  relative to control  (no 
competitor added)  is shown as a logit (In [% control/100-% control]) vs. log of unlabeled competitor 
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TABLE  I 
Proportion of Ig-la' in Preparation A of Fig. 1," Estimation by Addition of 
Limiting Quantities of [lzSI]A into Igola-Reactive Wells* 
Experiment 
[125I]A  Counts per 
minute 
Counts  Counts  bound + 
Nanograms  per  per  counts per 
added  minute  minute  minute 
added  bound  added 
IV 
V 
X lO  s  × 10  a  × 102 
40  2.32  0.956  0.35 
100  5.81  2.13  0.38 
200  10.75  4.00  0.35 
500  26.60  8.12  0.31 
1,000  50.33  13.34  0.26 
27  2.21  2.30  0.11 
55  4;37  4.61  0.10 
109  8.63  10.3  0.12 
219  16.53  15.83  0.09 
438  32.91  37.17  0.11 
875  65.94  88.66  0.13 
* Each count per minute value is the mean of triplicate determinations. The 
value for counts per minute bound was corrected for nonspecific uptake. 
shown (A). The remaining two preparations  (C, E) were not inhibitory in this assay; 
neither  were  7S  Ig  preparations  of B6,  C57BL/Ka,  or  Fab  fragments  of M173. 
Additional controls to show that specificity of this assay system is restricted  to Ig-la 
have been reported elsewhere  (17,  18). 
Noncompetitive  Binding of [125I]Ig-la'  and [1251]Ig-la  to Ig-la-Reactive  Wells.  A  direct 
estimate  of the  quantity  of Ig-la' in  preparation  A  of Fig.  1 was  made  as  follows. 
Limiting dilutions of [125]I-A were added to Ig-la-reactive wells. As anti-Ig-la was in 
excess, the percentage of [12s]I-A bound was independent of the amount added. Table 
I  shows representative  results of five such experiments.  As can be seen, 0.1-0.3%  of 
[12~]I-A was bound, which is consistent with a quantitative interpretation of the results 
in Fig.  1. With the same kind of procedure, the percentage of Ig-i a in 7S Ig of BALB/ 
c and in preparations  of M173, U10, and LPC-1 was estimated;  the values were 24, 
58, 64, and 91% respectively (not shown). 
Competitive Binding of [ta:I]Ig-la ' and [12sI]Ig-la  to Ig-la-Reactive  Wells.  To examine 
whether the affinity of anti-Ig-la  for Ig-la' was comparable to its affinity for Ig-la, 
we labeled  preparation  A  (of Fig.  1)  with  a31I ([131I]Ig-la') and  the  Ig-la myeloma 
protein  of U10  with  125I ([t25I]Ig-la).  The  simultaneous  addition  of both  labeled 
antigens to Ig-la-reactive wells enabled us to measure their binding under conditions 
in  which  each  would  have  to  compete  with  the  other.  The  quantity  of reactive 
[131I]Ig-la' and  [125I]Ig-la added  was  determined  by noncompetitive  assays  (of the 
kind shown in Table I) that were carried out in parallel to the above. Experimentally 
determined ratios of bound [lalI]Ig-1  a' to [12sIlIg-1 a were compared to those expected 
assuming the binding affinities  of [131I]Ig-la' (relative  binding affinity constant,  K') 
and [125I]Ig-la (relative binding affinity constant, K) were equal (K' =  K) or unequal 
(K'  ---  K/10). The basis for these calculations is shown in the Appendix. C.  L.  DEWITT AND M. J.  BOSMA 
TABLE II 
Competitive Binding of [lal l]  lg- l a" and [leal] Ig- l a to lg- l a-Reactive Wells* 
355 
Experiment 
Nanograms  Nanograms 
[~3'IlIg.la'  ['25IlIg-la 
Added  Per-  Added  Per- 
centage  centage 
bound  bound 
Ratio of bound ['31I]Ig-  la'/[lZSl]Ig  - la 
Observed  Expected 
K'  =  K  K'  =  K/10 
%  % 
0.076  100  0.189  100  0.425  0.402  0.273 
0.193  100  0.479  92  0.459  0.402  0.267 
0.773  88  1.942  77  0.450  0.402  0.207 
1.925  75  4.968  53  0.546  0.384  0.101 
II  0.080  100  0.394  98  0.202  0.204  0.094 
0.200  94  0.918  83  0.220  0.218  0.096 
0.796  69  3.745  69  0.212  0.212  0.070 
2.00  43  9.387  43  0.213  0.214  0.040 
* [lalI]Ig-la' is that of preparation  A of Fig. 1 and [125I]Ig-la  is that of U10 myeloma protein. 
Table II summarizes  the results of two competitive experiments.  First  to be noted 
is that  decreasing  fractions of [131I]Ig-la' and  [125I]Ig-la were bound  with  increasing 
total antigen  added,  thus demonstrating  both antigens  had to compete for antibody. 
Second, the ratios of nanograms of [131I]Ig-la'/[t25I]Ig  - la bound reflected the ratios of 
nanograms of [13tI]Ig-la'/[t25I]Ig  - I a added as would be expected of identical  antigens 
and  as predicted  from calculations  assuming  K'  =  K  (see Appendix).  If anything, 
more [131I]Ig-la' was bound  than  expected;  this probably reflects experimental  error 
in our estimate of the initial concentration  of Ig-la'. 
Discussion 
The  preceding  results  showed  that  certain  pools  of C.B-17  (and  BAB/14)  serum 
contained  detectable  Ig-la'. This antigen  was indistinguishable  from reference Ig-la 
proteins and represented  -0.1-0.3%  of the 7S serum Ig fraction.  Consistent  with our 
previous observations (1), Ig-la' production  appeared to be transient,  as not all  7S Ig 
preparations  of C.B-17  and  BAB-14  mice  had  detectable  Ig-la'. The  following  is a 
discussion of (a) the basis for considering Ig- la' identical to Ig- la, and (b) explanations 
for low, transient  productions  of Ig-1 a'. 
Evidence  that Ig-la' Is Equivalent to Ig-la.  The first question  to consider is whether 
detection  of Ig-la' could  be an experimental  artifact  relating to nonspecific  binding 
or  to  Ig-la-like crossreacting  determinants.  Evidence  against  this  idea  is as  follows: 
(a)  The assay for Ig-la' was highly specific, it  utilized specifically purified  anti-Ig-la 
and  homogenous  Ig-la  myeloma  proteins;  (b)  Ig-la'  did  not  act  as  an  incomplete 
competitor  as  is  typical  of cross-reacting  protein  antigens,  rather  it  could  displace 
completely  the  binding  of [~25I]Ig-la to  Ig-la-reactive wells  (Fig.  1);  (c)  The bound 
fraction  of Ig-la'  represented  0.1-0.3%  of the  7S  Ig  added  (preparation  A).  This 
compared  favorably  with  its  effectiveness  as  a  competitor;  i.e.,  to  get  comparable 
inhibition  of the binding of [125I]Ig-la to Ig-la-reactive wells, it was necessary to add 
-1,000-fold  more  7S Ig of preparation  A  than  Ig-la myeloma protein  (Fig.  1);  and 
(d) Direct measurements of competitive binding of [laaI]Ig-la' and [125I]Ig-la to Ig-la- 
reactive wells showed these two antigens  to be indistinguishable. 356  RADIOIMMUNE  ANALYSIS OF AN  UNEXPECTED MOUSE ALLOTYPE 
Possible Explanations for Low, Transient Production of Ig- l a' 
DEFICIENT  EXPRESSION  AND  STIMULATION  OF  IG-IA'  B  CELLS.  The presence of Ig-la' 
in  Ig-lb-producing  C.B-17  mice  could  result  from  leaky expression of a  normally 
silent Ig-la' locus. Manifestation of this at the cellular level could be low and variable 
numbers of Ig-la'-bearing B cells. 
It seems possible that heavy-chain-constant (CH) region genes for Ig-la' and Ig-lb 
may be expressed with different heavy-chain-variable (VH)  genes. If this were not so 
and members of the same set of VH genes were to randomly join with either CH gene, 
we would expect to see early and regular production of both Ig-la' and Ig-lb. That 
this does not occur with Ig-la' could reflect its association with a  small and distinct 
set of VH  regions  (Ig-la' locus). Serum Ig-la'  would then go undetected unless  the 
appropriate antigens were present to induce sufficient clonal proliferation of the few 
Ig- la'-bearing cells. 
The possibility that the putative Ig-la' locus might contain additional CH genes is 
suggested by our preliminary radioimmune evidence for Ig-4a' in pools A  and D  of 
Fig.  1 (our unpublished data)  (Ig-4a corresponds to BALB/c IgG1). This prompts us 
to speculate as before (18) that the mouse genome may contain several disjoint clusters 
of VH, CH and  allelic regulator  (RH)  genes.  The expression of a  given gene cluster 
would then depend on which RH allele is active. 
THYMUS-DEPENDENT  SUPPRESSION  OF  IG-IA t  B  CELLS.  Not mutually exclusive of the 
preceding considerations, C.B-17 mice might generate thymus-dependent immunity 
against Ig-la'-producing B cells. Unless such B cells were to appear early and regularly 
in the developing C.B-17 mouse, the host might be intolerant of their presence. 
Suggestive evidence for possible involvement ofcytotoxic or suppressor T  cells (Tcs 
cells)  in  Ig-la'  regulation comes from recent experiments. Earlier, we reported  (18) 
that  normal  allotype-congenic  mice  appear  to  contain  T  cells  that  can  prevent 
adoptively transferred lymphocytes of allotype-congenic partner mice from producing 
their respective allotypes. The strength of such allotype barriers varies according to 
the allotypes in question. In the case of C.B-17 vs. BALB/c, the barrier is relatively 
weak.  That  is,  after transfer of BALB/c lymphocytes to C.B-17  hosts, donor Ig-la 
appears and then disappears in many recipients. This does not happen when cells of 
the same donor are transferred to nude C.B-17 mice. In all nude recipients, donor Ig- 
la persists for as long as such mice have been tested (>10 wk after cell transfer)  (18, 
and our unpublished  observations). Thus, specific Tcs in normal C.B-17  mice may 
prevent Ig-la' B cells from producing Ig-la'. Such Tcs cells could serve as a primary 
or secondary regulatory system for maintaining  the silence of Ig-la'.  It is not clear 
what  structures  on  Ig-la'  B  cells  would  be  seen  as  foreign, although  they  would 
presumably be controlled by allotype-linked genes. 
From the data presented and cited, it seems certain that hidden mouse allotypes do 
in fact exist, but that specific regulatory mechanisms normally prevent their produc- 
tion.  Regulation  is  likely to  involve both  intra-  and  extracellular mechanisms.  To 
understand the latter will require identification of specific recognition elements and 
their controlling genes in a given regualtory network of lymphocytes. 
Appendix 
Basis for Calculation of Table II 
NONCOMPETITIVE  BINDING  OF  IG-IA  AND  IG-IA t  TO  IG-tA-REACTIVE  WELLS.  The initial C.  L.  DEWITT AND M. J.  BOSMA  357 
concentration  of  reactive  anti-Ig-la  (Abi  24.2  ng/well)  was  estimated  from  the 
maximum capacity of each well to bind [1251]Ig-la  in antigen excess. Similarly, initial 
concentrations of Ig-la (Ag  O and Ig-la' (Agi') were estimated from the quantities of 
[t25I]Ig- 1  a and [latI]Ig-  ! a' bound under conditions of antibody excess (Table I). Given 
the quantities of bound Ag (Ag.Ab) for each addition of Agi, and Abi  =  4.2 ng/well, 
the relative affinity constant  (K) of anti-Ig-la for Ig-la was calculated  to be  7.0  X 
1011 l/m. This assumes univalent binding of Ag and Ab in Ig-la-reactive wells. 
COMPETITIVE  BINDING  OF  IG-IA  AND  IG-IA  t  TO  IG-IA-REACTIVE  WELLS,  Equilibria 
expressions  involving  only  initial  (Agi,  Agi',  Abi)  and  bound  (Ag.Ab,  Ag'.Ab) 
concentrations  of the above terms can be written  as:  (1)  K  =  Ag-Ab/[(Abi -  Ag. 
Ab -  Ag'.Ab)  (Agi-  Ag.Ab)],  and  (2)  K'  =  Ag'-Ab/[(Abi -  Ag-Ab -  Ag'.Ab) 
(Agi' -  Ag'.Ab)] where equilibrium  concentrations are: Ab  --- Abi -  Ag.Ab -  Ag'. 
Ab,  Ag  =  Agi  -  Ag-Ab,  and  Ag'  =  Agi'  -  Ag'.Ab;  and  where  K  is  the  relative 
affinity constant of Ab for Ag, and K' is the relative affinity constant of Ab for Ag'. 
Assuming K' ~  K, 7,0  ×  10111/m, predicted values of bound Ag and Ag' (Ag. Ab, 
Ag'.Ab)  in expressions  (1)  and  (2)  were determined  by computer given the concen- 
trations of Agi and Agi' added to each Ag-reactive well and Abi  =  4.2 ng/well. The 
same was done assuming K' =  K/10. 
Summary 
We have used a radioimmune assay to confirm our earlier findings of an unexpected 
immunoglobulin  allotype in  Igb-congenic BALB/c  mice.  Although  these  mice were 
bred  to  exclude  the  IgG2a allotype  of BALB/c  (Ig-la),  an  Ig-la-like antigen  was 
detected  in  the  7S  Ig fraction of two  (of five) pooled serum samples, it  represented 
0.1-0.3% of the total 7S protein and was indistinguishable  from a  reference Ig-la. 
The detection of putative Ig-la in Igb-congenic mice is inconsistent with the notion 
that allotypes are products of allelic structural genes. It appears rather that expression 
of  Ig-la  is  controlled  by  allelic  regulator  genes  and  that  its  low  and  transient 
production in Igb-congenic mice results from incomplete negative regulation. 
Recewed  for publication  18 April 1979. 
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